Biosimulation Technology: Market Research Report

January 2015 | 164 pages | ID: B5020DD2662EN
Global Industry Analysts, Inc

Abstracts

This report analyzes the worldwide markets for Biosimulation Technology in US$ Thousand. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 42 companies including many key and niche players such as -

• Advanced Chemistry Development, Inc.
• Biovia
• Certara L.P
• Chemical Computing Group
• Entelos, Inc.

Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW

Biosimulation: Massively Benefiting Drug R&D
Current and Future Analysis
Application and End-user Areas

Table 1. Global Biosimulation Market by Application (2014): Percentage Share of Revenue in Drug Development, Drug Discovery, and Others (includes corresponding Graph/Chart)

Table 2. Global Biosimulation Market by End-user Sector (2014): Percentage Share of Revenue for Academic Research Institutes, Biotechnology/Drug Companies, Contract Research Organizations (CROs), Regulatory Organizations, and Others (includes corresponding Graph/Chart)

Biosimulation Offers Paradigm Shift in Drug Development
Key Market Drivers in a Nutshell
Market Restraints
Competition

2. GROWTH DRIVERS

Increasing Healthcare Expenditure Drives the Need for Drug Discovery and Development

Table 3. Per Capita Healthcare Expenditure in US$ by Select Country (includes corresponding Graph/Chart)

Table 4. Healthcare Expenditure as % of GDP by Select Country (includes corresponding Graph/Chart)

Increasing Incidence and Prevalence of CDDs: A Major Growth Driver

Table 5. Worldwide Incidence of Cancer in Million: 2012, 2020 & 2030 (includes corresponding Graph/Chart)

Table 6. Global Annual Medical Cost of CVD in US$ Billion (2010-2030) (includes corresponding Graph/Chart)

Aging Global Population Drives Advanced Drug R&D

Table 7. Global Population Statistics for the 65+ Age Group (2012) (includes corresponding Graph/Chart)

Table 8. Elderly Population (65+ Years) as a % of Total Population (2000 & 2025) (includes corresponding Graph/Chart)

High Costs Associated with Traditional Drug Discovery

Table 9. Escalating Costs of New Drug Development Over the Decades (includes corresponding Graph/Chart)

Table 10. US R&D Productivity Trends in Pharma Industry (2006- 2013) (includes corresponding Graph/Chart)

High Failure Rate of Late-Stage Drug Trials
List of Recent Late-stage Drug Failures (2014)
China and India: Hot Spots for R&D Investment

Table 11. Percentage Breakup of Global R&D Spending by Region (2012) (includes corresponding Graph/Chart)

Biosimulation Overcomes Challenges in Pediatric Drug Development

3. MARKET TRENDS – AN INSIGHT

Simulation Tools Take the Pressure off Mounting Life Science R&D Budgets

Table 12. Global Life Science R&D Expenditure (2011-2014): Total R&D Spending in US$ Billion (includes corresponding Graph/Chart)

Biosimulation Gets Neurodegenerative Disease Out of the Cul-de-sac
Marking New Avenues in Diabetes Research
Biosimulation Moving From Discovery Aid to Clinical Tool
Lung Biosimulation: Game Changer for OIP Development
Biosimulation for Drug Repositioning
Grid-based Docking Aids Biosimulation
Need for Better Models: A Major Factor Driving Innovation in the Market

4. TECHNOLOGY OVERVIEW

Biosimulation - A Brief Introduction
Drug Discovery and Development
Stages in Drug Development Process
Target identification
Target Validation
Lead Identification
Lead Optimization
Pre-Clinical Testing
Clinical Trials
Drug Discovery Technologies
Human Physiology
Mathematical Models and Biosimulation Technique
Bottom-up Modeling
Top-Down Modeling

5. PRODUCT LAUNCHES/APPROVALS

Certara Launches Simcyp In Vitro Analysis Toolkit Version 1.
Optimata Granted US Patent for Biosimulation Technology
Cognigen Releases Version 1. 3 of KIWI
Simulations Plus Releases Version 9. 0 of GastroPlus
Certara Launches Version 2. 0 of Cardiac Safety Simulator
Certara Releases Version 14 of Simcyp Simulator
Certara Receives FDA Grant for MechDermA
Physiomics Launches EasyAP
Rhenovia Pharma Develops Simulator for Epilepsy Mechanisms
Insilico Biotechnology Launches Simulation Platform for Virtual Organs

6. RECENT INDUSTRY ACTIVITY

Certara Merges Its Pharsight Consulting with Quantitative Solutions
Optivia Biotechnology and Rhenovia Pharma Sign Partnership Agreement
Physiomics Signs Contract with Merck Serono
PMDA Equips Pharmacometrics Team with Certara’s Biosimulation Solutions
CQDM and Alsace-Biovalley Collaborate on Biosimulation Platform
Dassault Systèmes Acquires Accelrys
Rhenovia Pharma Secures Series B Funding
Pharmacelsus and Insilico Biotechnology Collaborate for Preclinical Drug Analysis
Arsenal Capital Partners Acquires Certara
Entelos Enters Into Licensing Agreement with USFDA

7. FOCUS ON SELECT GLOBAL PLAYERS

Advanced Chemistry Development, Inc. (Canada)
Biovia (Formerly Accelrys) (US)
Certara L. P. (US)
Chemical Computing Group (Canada)
Entelos, Inc. (US)
In Silico Biosciences, Inc. (US)
InhibOx (UK)
Insilico Biotechnology AG (Germany)
LeadInvent Technologies (India)
Leadscope, Inc. (US)
Nimbus Therapeutics (US)
OpenEye Scientific Software Inc. (US)
Physiomics Plc. (UK)
Rhenovia Pharma SAS (France)
Schrodinger, LLC (US)
Simulations Plus, Inc. (US)

8. GLOBAL MARKET PERSPECTIVE

Table 13. World Recent Past, Current & Future Analysis for Biosimulation Technology by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

Table 14. World 8-Year Perspective for Biosimulation Technology by Geographic Region - Percentage Breakdown of Value Sales for US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World Markets for Years 2013, 2015 & 2020 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

A. Market Analysis
Biosimulation to Abate Life Sciences R&D Spending

Table 15. The US Life Science Industry Annual R&D Expenditure: 2011-2014 (includes corresponding Graph/Chart)

Ageing Population – Booster for Effective Drug Development

Table 16. North American Elderly Population by Age Group: 1975-2050 (includes corresponding Graph/Chart)

Rise in Chronic Disorders Drive Market Growth

Table 17. US Diabetics Population (2010-2017): Percentage Population with Diagnosed and Undiagnosed Diabetes (includes corresponding Graph/Chart)

Table 18. High Blood Pressure Prevalence in the US (2012): Prevalence Rates for Male and Female Population by Age Groups (includes corresponding Graph/Chart)

Table 19. High Blood Pressure Prevalence in the US (2012): Prevalence Rates for Male and Female Population by Ethnic Group (includes corresponding Graph/Chart)

Table 20. New Cancer Cases in the US by Gender and Affected Site: 2014E (includes corresponding Graph/Chart)

Product Launches
Strategic Corporate Developments
Key Players
B. Market Analytics

Table 21. The US Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

2. CANADA

A. Market Analysis
Increasing Incidence of Cancer: A Major Growth Driver

Table 22. New Cancer Cases in Canada by Gender and Affected Site: 2014E (includes corresponding Graph/Chart)

Strategic Corporate Development
Key Players
B. Market Analytics

Table 23. Canadian Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

3. JAPAN

A. Market Analysis
Graying Population Spurs Demand for Advanced Drug Development

Table 24. Japanese Elderly (65+ Years) Population: 2000-2020 (includes corresponding Graph/Chart)

Strategic Corporate Development
B. Market Analytics

Table 25. Japanese Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

4. EUROPE

A. Market Analysis
Regulatory Authorities Stress on Paradigm Shift in Drug Development
Ageing Population Boosts Demand

Table 26. European Country-wise Statistics of 60+ Population as % of Total Population: 2013 (includes corresponding Graph/Chart)

B. Market Analytics

Table 27. European Recent Past, Current & Future Analysis for Biosimulation Technology by Geographic Region - France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets Independently Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

Table 28. European 8-Year Perspective for Biosimulation Technology by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia, and Rest of Europe Markets for Years 2013, 2015 & 2020 (includes corresponding Graph/Chart)

4A. FRANCE

A. Market Analysis
Strategic Corporate Developments
Rhenovia Pharma SAS – A Key Player
B. Market Analytics

Table 29. French Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

4B. GERMANY

A. Market Analysis
Product Launch
Strategic Corporate Development
Insilico Biotechnology AG – A Key Player
B. Market Analytics

Table 30. German Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

4C. ITALY

Market Analysis

Table 31. Italian Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

4D. UNITED KINGDOM

A. Market Analysis
Product Launch
Strategic Corporate Development
Key Players
B. Market Analytics

Table 32. The UK Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

4E. SPAIN

Market Analysis

Table 33. Spanish Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

4F. RUSSIA

Market Analysis

Table 34. Russian Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

4G. REST OF EUROPE

Market Analysis

Table 35. Rest of European Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC

A. Market Analysis
Growing Population and Aging Demographic Drive Demand for Advanced Drug Development

Table 36. Population Statistics in Asia (Including Japan) & Percentage of Population Aged Above 65 Years (includes corresponding Graph/Chart)

Leadinvent Technologies (India) – A Key Player
B. Market Analytics

Table 37. Asia-Pacific Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

6. LATIN AMERICA

Market Analysis

Table 38. Latin American Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

7. REST OF WORLD

A. Market Analysis
Product Launch
B. Market Analytics

Table 39. Rest of World Recent Past, Current & Future Analysis for Biosimulation Technology Analyzed with Annual Sales Figures in US$ Thousand for Years 2013 through 2020 (includes corresponding Graph/Chart)

IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 42 (including Divisions/Subsidiaries - 44)
The United States (18)
Canada (2)
Japan (2)
Europe (19)
  France (2)
  Germany (4)
  The United Kingdom (6)
  Spain (1)
  Rest of Europe (6)
Asia-Pacific (Excluding Japan) (1)
Middle East (2)